Lv51
1120 积分 2021-11-04 加入
Giredestrant for Estrogen Receptor-Positive, HER2 Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Studyy
7个月前
已关闭
A Phase 1 dose escalation and expansion trial of the next-generationoral SERD camizestrant in women with ER-positive, HER2-negativeadvanced breast cancer: SERENA-1 monotherapy results
7个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post.menopausal women with oestrogen receptor-positive, HER2-negative advancedbreast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
7个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
7个月前
已完结
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer
9个月前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
10个月前
已完结
Cancer incidence and mortality in China, 2022
1年前
已完结
Real-world Neoadiuvant Treatment Patterns andOutcomes in Resected Non-Small Cell Lung cancer
1年前
已完结
Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)
1年前
已完结
Trends in rare disease drug development
1年前
已完结
皖公网安备34019202002308
